Cargando…

Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up

As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Coppola, Annachiara, Buonerba, Carlo, Cardinale, Davide, Lo Conte, Gabriella, Sansone, Donato, Rofrano, Giuseppe, De Vita, Sabato, Morgante, Maria, Triassi, Maria, Atripaldi, Luigi, Brambilla, Gianfranco, Sabatino, Rocco, Pierri, Andrea, Pacella, Daniela, Pizzolante, Antonio, Pierri, Biancamaria, Ferrucci, Veronica, Zollo, Massimo, Capasso, Mario, Stringhini, Silvia, Ascierto, Paolo Antonio, Roperto, Sante, Cerino, Pellegrino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718636/
https://www.ncbi.nlm.nih.gov/pubmed/34976939
http://dx.doi.org/10.3389/fpubh.2021.801609
_version_ 1784624769688141824
author Coppola, Annachiara
Buonerba, Carlo
Cardinale, Davide
Lo Conte, Gabriella
Sansone, Donato
Rofrano, Giuseppe
De Vita, Sabato
Morgante, Maria
Triassi, Maria
Atripaldi, Luigi
Brambilla, Gianfranco
Sabatino, Rocco
Pierri, Andrea
Pacella, Daniela
Pizzolante, Antonio
Pierri, Biancamaria
Ferrucci, Veronica
Zollo, Massimo
Capasso, Mario
Stringhini, Silvia
Ascierto, Paolo Antonio
Roperto, Sante
Cerino, Pellegrino
author_facet Coppola, Annachiara
Buonerba, Carlo
Cardinale, Davide
Lo Conte, Gabriella
Sansone, Donato
Rofrano, Giuseppe
De Vita, Sabato
Morgante, Maria
Triassi, Maria
Atripaldi, Luigi
Brambilla, Gianfranco
Sabatino, Rocco
Pierri, Andrea
Pacella, Daniela
Pizzolante, Antonio
Pierri, Biancamaria
Ferrucci, Veronica
Zollo, Massimo
Capasso, Mario
Stringhini, Silvia
Ascierto, Paolo Antonio
Roperto, Sante
Cerino, Pellegrino
author_sort Coppola, Annachiara
collection PubMed
description As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29–59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2.
format Online
Article
Text
id pubmed-8718636
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87186362022-01-01 Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up Coppola, Annachiara Buonerba, Carlo Cardinale, Davide Lo Conte, Gabriella Sansone, Donato Rofrano, Giuseppe De Vita, Sabato Morgante, Maria Triassi, Maria Atripaldi, Luigi Brambilla, Gianfranco Sabatino, Rocco Pierri, Andrea Pacella, Daniela Pizzolante, Antonio Pierri, Biancamaria Ferrucci, Veronica Zollo, Massimo Capasso, Mario Stringhini, Silvia Ascierto, Paolo Antonio Roperto, Sante Cerino, Pellegrino Front Public Health Public Health As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29–59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2. Frontiers Media S.A. 2021-12-17 /pmc/articles/PMC8718636/ /pubmed/34976939 http://dx.doi.org/10.3389/fpubh.2021.801609 Text en Copyright © 2021 Coppola, Buonerba, Cardinale, Lo Conte, Sansone, Rofrano, De Vita, Morgante, Triassi, Atripaldi, Brambilla, Sabatino, Pierri, Pacella, Pizzolante, Pierri, Ferrucci, Zollo, Capasso, Stringhini, Ascierto, Roperto and Cerino. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Coppola, Annachiara
Buonerba, Carlo
Cardinale, Davide
Lo Conte, Gabriella
Sansone, Donato
Rofrano, Giuseppe
De Vita, Sabato
Morgante, Maria
Triassi, Maria
Atripaldi, Luigi
Brambilla, Gianfranco
Sabatino, Rocco
Pierri, Andrea
Pacella, Daniela
Pizzolante, Antonio
Pierri, Biancamaria
Ferrucci, Veronica
Zollo, Massimo
Capasso, Mario
Stringhini, Silvia
Ascierto, Paolo Antonio
Roperto, Sante
Cerino, Pellegrino
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
title Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
title_full Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
title_fullStr Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
title_full_unstemmed Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
title_short Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
title_sort durability of humoral immune responses to sars-cov-2 in citizens of ariano irpino (campania, italy): a longitudinal observational study with an 11.5-month follow-up
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718636/
https://www.ncbi.nlm.nih.gov/pubmed/34976939
http://dx.doi.org/10.3389/fpubh.2021.801609
work_keys_str_mv AT coppolaannachiara durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT buonerbacarlo durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT cardinaledavide durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT locontegabriella durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT sansonedonato durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT rofranogiuseppe durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT devitasabato durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT morgantemaria durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT triassimaria durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT atripaldiluigi durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT brambillagianfranco durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT sabatinorocco durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT pierriandrea durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT pacelladaniela durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT pizzolanteantonio durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT pierribiancamaria durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT ferrucciveronica durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT zollomassimo durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT capassomario durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT stringhinisilvia durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT asciertopaoloantonio durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT ropertosante durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup
AT cerinopellegrino durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup